article thumbnail

State Boards of Pharmacy Missing in Action During Opioid Crisis

Policy Prescription

state boards of pharmacy to properly regulate pharmacies that irresponsibly and too often illegally profited from opioid drug sales to patients. Despite the law requiring the reporting of suspicious orders, the Gazette-Mail reported that between 2001-2012 the board received only two reports , both from Cardinal Health.

article thumbnail

Chipscreen and HISUN reach a strategic cooperation

The Pharma Data

As the world’s first PPAR pan agonist that completed two confirmatory phase III clinical trials, Chiglitazar Sodium has shown significant and long-lasting hypoglycemic effects in a series of clinical studies, as well as other comprehensive effects including significant insulin sensitization and blood lipid regulation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

FDA Law Blog: Biosimilars

Not surprisingly, then-presidential candidate Asa Hutchinson, DEA Administrator from 2001 to 2003, did not sign the letter. A state-regulated cannabis industry better protects consumers than the illicit market or the unregulated intoxicating hemp-derived marketplace. January 29, 2024).

article thumbnail

Another Update on Medical Abortion Litigation

Drug & Device Law

341 (2001), is so important. 1989) (refusing to “upset the FDA’s scheme for regulating drugs and cosmetics”); Mitchell v. The Doctors therefore sustain a concrete injury when they are forced to divert time and resources away from their regular patients. That’s why Buckman Co. Plaintiffs Legal Committee , 531 U.S. FDA , 727 F.

FDA 52
article thumbnail

Another Update on Medical Abortion Litigation

Drug & Device Law

In our line of work, much of what we do depends on the continuing validity of how the FDA regulates prescription medical products. 341 (2001), is so important. 1989) (refusing to “upset the FDA’s scheme for regulating drugs and cosmetics”); Mitchell v. That’s why Buckman Co. Plaintiffs Legal Committee , 531 U.S. FDA , 727 F.

article thumbnail

Who Needs a Lawyer in the Eleventh Circuit?

Drug & Device Law

She also tried to sue three new defendants – a doctor, a medical society and the FDA itself. 341 (2001). What the offending “component” or “material” was isn’t stated, nor how anything was “inconsistent” with some unidentified “regulation” or “requirement.” Plaintiffs Legal Committee , 531 U.S. 2019 WL 6766574, at *3.

FDA 59
article thumbnail

Life-Saving Drugs and Chicken Bones: California Court Expands Innovator Duties of Care

Drug & Device Law

The FDA approved the defendant’s first TDF drug in 2001, and the company started its first clinical trial on a different compound—tenofovir alafenamide (“TAF”)—about a year later. This novel duty has implications far beyond FDA-regulated products.